FDA Breakthrough Therapy designation granted to zovegalisib for PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial ...
Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline developmentCompelling efficacy and tolerability data for zovegalisib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results